

@article{Janecka2016ClinicalAM, title={Clinical and Molecular Features of Laron Syndrome, A Genetic Disorder Protecting from Cancer.}, author={A. Janecka and Marta KoÅodziej-Rzepa and B. Biesaga}, journal={In vivo}, year={2016}, volume={30 4}, pages={. 375-81 } } A. Janecka, Marta KoÅodziej-Rzepa, B. Biesaga. The clinical portion of this book represents a compendium of the Israeli team’s experience with LS from discovery, the struggle to define its pathogenesis, to determine the consequences if not treated by IGF-I, and the results of long-term IGF-I treatment. Reference to studies by other investigators are included when found appropriate.

Â 255 Zvi Laron and Rivka Kauli 30 Insulin Secretion and Carbohydrate Metabolism in Patients with Laron Syndrome: From Hypoglycemia to Diabetes Mellitus . . . 259 Zvi Laron 31 Liver Enzymes in Patients with Laron Syndrome . . . The clinical portion of this book represents a compendium of the Israeli team’s experience with LS from discovery, the struggle to define its pathogenesis, to determine the consequences if not treated by IGF-I, and the results of long-term IGF-I treatment. Reference to studies by other investigators are included when found appropriate.